Analysts forecast that Agenus Inc (NASDAQ:AGEN) will announce $5.19 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for Agenus’ earnings, with estimates ranging from $2.9 million to $6.66 million. Agenus reported sales of $6.59 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 21.2%. The company is scheduled to report its next earnings report on Thursday, July 27th.

On average, analysts expect that Agenus will report full year sales of $5.19 million for the current financial year, with estimates ranging from $46.97 million to $66.6 million. For the next year, analysts expect that the business will post sales of $27.63 million per share, with estimates ranging from $12.75 million to $35.6 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Agenus.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.14. The business had revenue of $26.96 million during the quarter, compared to the consensus estimate of $5.22 million. Agenus had a negative net margin of 472.80% and a negative return on equity of 359.98%.

AGEN has been the subject of several research analyst reports. Maxim Group reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Agenus in a report on Sunday, April 23rd. HC Wainwright set a $5.00 price objective on Agenus and gave the stock a “hold” rating in a report on Thursday, February 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. Agenus has a consensus rating of “Hold” and a consensus price target of $6.33.

WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/05/10/5-19-million-in-sales-expected-for-agenus-inc-agen-this-quarter.html.

In related news, major shareholder Corp Incyte bought 10,000,000 shares of the stock in a transaction that occurred on Tuesday, February 14th. The shares were bought at an average cost of $6.00 per share, for a total transaction of $60,000,000.00. Following the completion of the transaction, the insider now owns 17,763,968 shares of the company’s stock, valued at $106,583,808. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Garo H. Armen bought 100,000 shares of the stock in a transaction that occurred on Wednesday, April 12th. The shares were bought at an average price of $3.35 per share, for a total transaction of $335,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,389,021 shares of the company’s stock, valued at approximately $4,653,220.35. The disclosure for this purchase can be found here. Insiders own 7.60% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Compagnie Lombard Odier SCmA bought a new position in Agenus during the third quarter valued at $108,000. A.R.T. Advisors LLC bought a new position in Agenus during the fourth quarter valued at $101,000. AQR Capital Management LLC bought a new position in Agenus during the fourth quarter valued at $143,000. Quotient Investors LLC increased its position in Agenus by 8.8% in the first quarter. Quotient Investors LLC now owns 47,000 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 3,800 shares during the period. Finally, First Allied Advisory Services Inc. increased its position in Agenus by 25.0% in the fourth quarter. First Allied Advisory Services Inc. now owns 50,000 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 10,000 shares during the period. Institutional investors own 45.40% of the company’s stock.

Agenus (NASDAQ:AGEN) opened at 3.78 on Wednesday. The firm has a 50 day moving average of $3.64 and a 200 day moving average of $4.13. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49. The firm’s market cap is $374.67 million.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

5 Day Chart for NASDAQ:AGEN

Get a free copy of the Zacks research report on Agenus (AGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Agenus Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc and related companies with MarketBeat.com's FREE daily email newsletter.